secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2025-02-28T23:59:59+00:00
Accession:  0001023024-25-000012
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharma Q4 net rev $190.6M (+44.8%), adj EPS $1.63; raises 2025 guidance
---------------------------------------------------------------------------

- Record Q4 net rev $190.6M (+44.8% YoY); organic growth (ex-Alimera) +23.8%.
- Rare Disease rev $87.0M: Cortrophin Gel $59.4M (+42.3%), ILUVIEN/YUTIQ $27.6M.
- Adj. non-GAAP EBITDA $50.0M (+65.7%); diluted GAAP loss per share $0.55.
- Adj. non-GAAP diluted EPS $1.63 vs $1.00 in prior year quarter.
- 2025 guidance raised: rev $756-776M, adj. EBITDA $190-200M, adj. EPS $6.12-6.49.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302425000012/0001023024-25-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302425000012/ani-20250228.htm
  HTML page:      https://secwatch.observer/filing/0001023024-25-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer